• 1

    UNICEF, 2007. State of the World’s Children 2008: Child Survival, 1–154.

  • 2

    Campbell JD, Sow S, Levine MM, Kotloff KL, 2004. The causes of hospital admission and death among children in Bamako, Mali. J Trop Pediatr 50 :158–163.

    • Search Google Scholar
    • Export Citation
  • 3

    Sow SO, Diallo S, Campbell JD, Tapia MD, Keita T, Keita MM, Murray P, Kotloff KL, Levine MM, 2005. Burden of invasive disease caused by Haemophilus influenzae type b in Bamako, Mali: impetus for routine infant immunization with conjugate vaccine. Pediatr Infect Dis J 24 :533–537.

    • Search Google Scholar
    • Export Citation
  • 4

    Käyhty H, Peltola H, Karanko V, Mäkelä PH, 1983. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 147 :1100.

    • Search Google Scholar
    • Export Citation
  • 5

    Campbell JD, Kotloff KL, Sow SO, Tapia M, Keita MM, Keita T, Diallo S, Hormazabal JC, Murray P, Levine MM, 2004. Invasive pneumococcal infections among hospitalized children in Bamako, Mali. Pediatr Infect Dis J 23 :642–649.

    • Search Google Scholar
    • Export Citation
  • 6

    Lagos R, Valenzuela MT, Levine OS, Losonsky GA, Erazo A, Wasserman SS, Levine MM, 1998. Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens. Lancet 351 :1472–1476.

    • Search Google Scholar
    • Export Citation
  • 7

    Campbell JD, Lagos R, Levine MM, Losonsky GA, 2002. Standard and alternative regimens of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate vaccine) elicit comparable antibody avidities in infants. Pediatr Infect Dis J 21 :822–826.

    • Search Google Scholar
    • Export Citation
  • 8

    Blackwelder WC, 1993. Sample size and power for prospective analysis of relative risk. Stat Med 12 :691–698.

  • 9

    Adams WG, Deaver KA, Cochi SL, Plikaytis BD, Zell ER, Broome CV, Wenger JD, 1993. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 269 :221–226.

    • Search Google Scholar
    • Export Citation
  • 10

    Wenger JD, DiFabio J, Landaverde JM, Levine OS, Gaafar T, 1999. Introduction of Hib conjugate vaccines in the non-industrialized world: experience in four “newly adopting” countries. Vaccine 18 :736–742.

    • Search Google Scholar
    • Export Citation
  • 11

    Lagos R, Horwitz I, Toro J, San Martin O, Abrego P, Bustamante C, Wasserman SS, Levine OS, Levine MM, 1996. Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections. Pediatr Infect Dis J 15 :216–222.

    • Search Google Scholar
    • Export Citation
  • 12

    Ramkissoon A, Coovadia HM, Jugnundan P, Willems P, Clemens BR, 2001. A new combined DTP-HBV-Hib vaccine–strategy for incorporation of Hib vaccination into childhood immunisation programmes. S Afr Med J 91 :864–869.

    • Search Google Scholar
    • Export Citation
  • 13

    Mulholland K, Hilton S, Adegbola R, Usen S, Oparaugo A, Omosigho C, Weber M, Palmer A, Schneider G, Jobe K, Lahai G, Jaffar S, Secka O, Lin K, Ethevenaux C, Greenwood B, 1997. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate for prevention of pneumonia and meningitis in Gambian infants. Lancet 349 :1191–1197.

    • Search Google Scholar
    • Export Citation
  • 14

    Mulholland EK, Adegbola RA, 1998. The Gambian Haemophilus influenzae type b vaccine trial: what does it tell us about the burden of Haemophilus influenzae type b disease? Pediatr Infect Dis J 17 :S123–S125.

    • Search Google Scholar
    • Export Citation
  • 15

    Levine OS, Lagos R, Munoz A, Villaroel J, Alvarez AM, Abrego P, Levine MM, 1999. Defining the burden of pneumonia in children preventable by vaccination against Haemophilus influenzae type b. Pediatr Infect Dis J 18 :1060–1064.

    • Search Google Scholar
    • Export Citation
  • 16

    Gessner BD, Sutanto A, Linehan M, Djelantik IG, Fletcher T, Gerudug IK, Ingerani, Mercer D, Moniaga V, Moulton LH, Moulton LH, Mulholland K, Nelson C, Soemohardjo S, Steinhoff M, Widjaya A, Stoeckel P, Maynard J, and Arjoso S, 2005. Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial. Lancet 365 :43–52.

    • Search Google Scholar
    • Export Citation
  • 17

    Campagne G, Garba A, Schuchat A, Boulanger D, Plikaytis BD, Ousseini M, Chippaux JP, 1998. Response to conjugate Haemophilus influenzae B vaccine among infants in Niamey, Niger. Am J Trop Med Hyg 59 :837–842.

    • Search Google Scholar
    • Export Citation
  • 18

    Adegbola RA, Secka O, Lahai G, Lloyd-Evans N, Njie A, Usen S, Oluwalana C, Obaro S, Weber M, Corrah T, Mulholland K, McAdam K, Greenwood B, Milligan PJ, 2005. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet 366 :144–150.

    • Search Google Scholar
    • Export Citation
  • 19

    von Gottberg A, de Gouveia L, Madhi SA, du Plessis M, Quan V, Soma K, Huebner R, Flannery B, Schuchat A, Klugman K, 2006. Impact of conjugate Haemophilus influenzae type b (Hib) vaccine introduction in South Africa. Bull World Health Organ 84 :811–818.

    • Search Google Scholar
    • Export Citation
  • 20

    Cowgill KD, Ndiritu M, Nyiro J, Slack MP, Chiphatsi S, Ismail A, Kamau T, Mwangi I, English M, Newton CR, Feikin DR, Scott JA, 2006. Effectiveness of Haemophilus influenzae type b conjugate vaccine introduction into routine childhood immunization in Kenya. JAMA 296 :671–678.

    • Search Google Scholar
    • Export Citation
  • 21

    Daza P, Banda R, Misoya K, Katsulukuta A, Gessner BD, Katsande R, Mhlanga BR, Mueller JE, Nelson CB, Phiri A, Molyneux EM, Molyneux ME, 2006. The impact of routine infant immunization with Haemophilus influenzae type b conjugate vaccine in Malawi, a country with high human immunodeficiency virus prevalence. Vaccine 24 :6232–6239.

    • Search Google Scholar
    • Export Citation
  • 22

    Lim SS, Stein DB, Charrow A, Murray CJ, 2008. Tracking progress towards universal childhood immunisation and the impact of global initiatives: a systematic analysis of three-dose diphtheria, tetanus, and pertussis immunisation coverage. Lancet 372 :2031–2046.

    • Search Google Scholar
    • Export Citation
  • 23

    Tapia MD, Pasetti MF, Cuberos L, Sow SO, Doumbia MN, Bagayogo M, Kotloff KL, Levine MM, 2006. Measurement of tetanus antitoxin in oral fluid: a tool to conduct serosurveys. Pediatr Infect Dis J 25 :819–825.

    • Search Google Scholar
    • Export Citation
  • 24

    Levine OS, Granoff D, Lagos R, Fritzell B, Levine MM, 1997. Factors associated with a superior antibody response to a single dose of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine administered to Chilean infants at 2 months of age. Vaccine 15 :325–328.

    • Search Google Scholar
    • Export Citation
  • 25

    Hoppenbrouwers K, Lagos R, Swennen B, Ethevenaux C, Knops J, Levine MM, Desmyter J, 1998. Safety and immunogenicity of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-pertussis (DTP) combination vaccine administered in a dual-chamber syringe to infants in Belgium and Chile. Vaccine 16 :921–927.

    • Search Google Scholar
    • Export Citation
  • 26

    Adegbola RA, Usen SO, Weber M, Lloyd-Evans N, Jobe K, Mulholland K, McAdam KP, Greenwood BM, Milligan PJ, 1999. Haemophilus influenzae type b meningitis in The Gambia after introduction of a conjugate vaccine. Lancet 354 :1091–1092.

    • Search Google Scholar
    • Export Citation
  • 27

    Howie SR, Antonio M, Akisanya A, Sambou S, Hakeem I, Secka O, Adegbola RA, 2007. Re-emergence of Haemophilus influenzae type b (Hib) disease in The Gambia following successful elimination with conjugate Hib vaccine. Vaccine 25 :6305–6309.

    • Search Google Scholar
    • Export Citation
  • 28

    Lewis RF, Kisakye A, Gessner BD, Duku C, Odipio JB, Iriso R, Nansera D, Braka F, Makumbi I, Kekitiinwa A, 2008. Action for child survival: elimination of Haemophilus influenzae type b meningitis in Uganda. Bull World Health Organ 86 :292–301.

    • Search Google Scholar
    • Export Citation
  • 29

    Muganga N, Uwimana J, Fidele N, Gahimbare L, Gessner BD, Mueller JE, Mhlanga BR, Katsande R, Herbinger KH, Rugambwa C, 2007. Haemophilus influenzae type b conjugate vaccine impact against purulent meningitis in Rwanda. Vaccine 25 :7001–7005.

    • Search Google Scholar
    • Export Citation
  • 30

    Renner LA, Newman MJ, Ahadzie L, Antwi-Agyei KO, and Eshetu M, 2007. Introduction of Haemophilus influenzae type B conjugate vaccine into routine immunization in Ghana and its impact on bacterial meningitis in children younger than five years. Pediatr Infect Dis J 26 :356–358.

    • Search Google Scholar
    • Export Citation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

 

 

Haemophilus influenzae Type b Conjugate Vaccine Introduction in Mali: Impact on Disease Burden and Serologic Correlate of Protection

View More View Less
  • 1 Centre pour le Développement des Vaccins, Mali (CVD-Mali), Bamako, Mali; Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland; The Clinical Bacteriology Laboratory and the Pediatric Service, Gabriel Touré Hospital, Bamako, Mali
Restricted access

In Bamako, Mali, where surveillance revealed a high incidence of Haemophilus influenzae type b (Hib) invasive disease, Hib conjugate vaccine was introduced into the Expanded Program on Immunization and the impact assessed. Annual confirmed Hib hospitalizations for infants 0–11 months of age fell from 175/105 to 44/105 (P < 0.001); among infants 6–7 months of age Hib hospitalizations fell from 377/105 to 69/105, (82% decrease, P < 0.001). Invasive Streptococcus pneumoniae hospitalizations remained unchanged. In a baseline serosurvey, only 3/200 infants 6–7 months of age (1.5%) had protective anti-polyribosylribitol phosphate (PRP) titers ≥ 0.15 μg/mL and 1(0.5%) had ≥ 1.0 μg/mL. In serosurveys 18 and 30 months after vaccine introduction, 168/201 (84%) and 184/200 (92%) infants, respectively, had titers ≥ 0.15 μg/mL and 141/201 (70%) and 163/200 (82%) had titers ≥ 1.0 μg/mL. Introduction of Hib vaccine led to rises in anti-PRP seroprevalence, significant reductions in Hib disease, and all-cause hospitalizations, whereas S. pneumoniae disease remained unchanged.

Save